Valuation of Medical Innovation in Orphan Diseases with a Focus on Small Investors and Limited Diversifiable Risks

Journal of Market Access & Health Policy · Published 2026-08-05 · DOI 10.3390/jmahp14030047

Free full text

Authors (2)

Mark Nuijten, Pieter van Gelder

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Nuijten, M., Gelder, P. (2026). Valuation of Medical Innovation in Orphan Diseases with a Focus on Small Investors and Limited Diversifiable Risks. Journal of Market Access & Health Policy. https://doi.org/10.3390/jmahp14030047

Related articles

• Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada · Journal of Market Access & Health Policy · 2026 · Same journal
• Joint Clinical Assessment in the EU HTA Regulation—Would Drugs Supported by Single-Arm Trials Fit Under Evaluation? · Journal of Market Access & Health Policy · 2026 · Same journal
• Assessment and Appraisal of Drug Innovativeness in Italy: Ultimate Evidence on Key Drivers and Consistency · Journal of Market Access & Health Policy · 2026 · Same journal
• Addressing Unmet Medical Needs in Drug Development: Assessment and Implications for Regulatory and Clinical Development Strategies · Journal of Market Access & Health Policy · 2026 · Same journal
• Analysis of How the Term “Shall” Is Understood and Applied to the EU-HTA Regulation · Journal of Market Access & Health Policy · 2026 · Same journal
• Development of a Performance Measurement Framework for European Health Technology Assessment: Stakeholder-Centric Key Performance Indicators Identified in a Delphi Approach by the European Access Academy · Journal of Market Access & Health Policy · 2026 · Same journal
• Primary Care or Primary Problem? Aligning Access Pathways with Patient Needs Across the Care Continuum · Journal of Market Access & Health Policy · 2026 · Same journal
• Comparative Cost Evaluation of Managed Entry Agreement Techniques Using Real-World Data from High-Cost Anticancer Drugs in Thailand · Journal of Market Access & Health Policy · 2026 · Same journal
• Direct Public-Payer Costs of Dialysis Therapies in Greece: A Patient-Level Micro-Costing Study Across Modality and Provider Sector · Journal of Market Access & Health Policy · 2026 · Same journal
• EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making · Journal of Market Access & Health Policy · 2025 · Same journal